UBS Group
NXTC icon

UBS Group’s NextCure NXTC Stock Holding History

UBS Group’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$951 Buy
594
+256
+76% +$1.89K ﹤0.01% 9685
2026
Q1 		$3.61K Hold
338
– – ﹤0.01% 9058
2025
Q4 		$4.8K Sell
338
-263
-44% -$2.73K ﹤0.01% 8778
2025
Q3 		$3.52K Sell
601
-424
-41% -$2.22K ﹤0.01% 9037
2025
Q2 		$5.66K Buy
1,025
+314
+44% +$1.69K ﹤0.01% 9151
2025
Q1 		$4.1K Buy
711
+361
+103% +$3.18K ﹤0.01% 9146
2024
Q4 		$3.24K Sell
350
-106
-23% -$1.56K ﹤0.01% 8906
2024
Q3 		$7.49K Sell
456
-371
-45% -$6.83K ﹤0.01% 7901
2024
Q2 		$15.8K Sell
827
-74
-8% -$1.44K ﹤0.01% 7457
2024
Q1 		$24.1K Buy
901
+379
+73% +$6.53K ﹤0.01% 6837
2023
Q4 		$7.14K Sell
522
-453
-46% -$6.57K ﹤0.01% 7644
2023
Q3 		$15.1K Sell
975
-330
-25% -$6.3K ﹤0.01% 6939
2023
Q2 		$28.2K Buy
1,305
+244
+23% +$4.8K ﹤0.01% 6743
2023
Q1 		$18.9K Buy
1,061
+175
+20% +$3.37K ﹤0.01% 7128
2022
Q4 		$15K Buy
886
+55
+7% +$1.26K ﹤0.01% 8022
2022
Q3 		$27K Buy
831
+54
+7% +$2.75K ﹤0.01% 7006
2022
Q2 		$44K Buy
777
+14
+2% +$731 ﹤0.01% 6021
2022
Q1 		$45K Buy
763
+528
+225% +$33K ﹤0.01% 6605
2021
Q4 		$17K Buy
235
+232
+7,733% +$19.4K ﹤0.01% 8071
2021
Q3 		$0 Buy
3
+1
+50% +$88 ﹤0.01% 9910
2021
Q2 		$0 Sell
2
-175
-99% -$17.9K ﹤0.01% 9672
2021
Q1 		$21K Sell
177
-467
-73% -$67.6K ﹤0.01% 7339
2020
Q4 		$84K Buy
644
+640
+16,000% +$82.7K ﹤0.01% 5801
2020
Q3 		$0 Buy
+4
New +$492 ﹤0.01% 8281
2020
Q2 		– Sell
-763
Closed -$339K – 8238
2020
Q1 		$339K Buy
763
+717
+1,559% +$383K ﹤0.01% 4309
2019
Q4 		$31K Sell
46
-158
-77% -$79.3K ﹤0.01% 6618
2019
Q3 		$75K Buy
204
+84
+70% +$27.3K ﹤0.01% 5942
2019
Q2 		$22K Buy
+120
New +$24.9K ﹤0.01% 6547

Other funds holding NXTC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

UBS Group's NXTC Position: Q2 2026 in Review

UBS Group increased its NextCure (NXTC) stake by 76% in Q2 2026, buying an estimated $1.89K and bringing the position to 594 shares worth $951. The position accounts for ﹤0.01% of the portfolio, ranked #9685.

UBS Group first reported a position in NXTC in Q2 2019 and has held it in 28 quarters since. The position peaked at $339K in Q1 2020. 17 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • UBS Group held 594 shares of NextCure worth $951 as of Q2 2026.
  • UBS Group bought 256 NextCure shares in Q2 2026, an estimated $1.89K.
  • NextCure made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9685 holding.
  • UBS Group first reported a position in NextCure in Q2 2019 and has held it in 28 quarters since.
  • UBS Group's NextCure position peaked at $339K in Q1 2020.
  • 17 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.